BioMarin buys ZyStor for $22mm plus potential earnouts
BioMarin Pharmaceutical Inc. (orphan diseases) is paying $22mm up front in cash to acquire private biotech ZyStor Therapeutics Inc., which is focused on enzyme replacement therapies (ERT) for lysosomal storage disorders. BioMarin could spend another $93mm if certain development, regulatory, and commercial milestones are met.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com